Short Bowel Syndrome Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

MARKET OVERVIEW

Short bowel syndrome (SBS) is a digestive condition characterised by poor nutrient absorption. SBS is commonly observed in people who have had small parts of their intestines removed, have significant damage to the small intestine, and have limited motility inside the intestines. SBS patients are unable to absorb enough water, minerals, fat, vitamins, protein, calories, and other nutrients from their food. SBS might have mild, moderate, or severe symptoms. Medication like, glucagon like peptide, proton pump inhibitors, H2 blockers, and other therapies are commonly used to treat SBS.

MARKET SCOPE

The "Global Short Bowel Syndrome Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the short bowel syndrome market with detailed market segmentation by drug class and distribution channel. The report provides key statistics on the market status of the leading short bowel syndrome market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

•   Based on drug class the market is segmented as, glucagone-like peptide, H2 blockers, proton pump inhibitors and others.
  
•   Based on distribution channel the market is segmented as, hospital pharmacies, retail pharmacies and online sales.
  

MARKET DYNAMICS
Drivers:

•   Rising prevalence of short bowel syndrome and other gastrointestinal disorders.
  
•   High cost of parenteral nutrition as major of the SBS patient are on parenteral nutrition.
  
•   Extensive R&D efforts by pharmaceutical companies to develop novel therapies for SBS is expected to fuel the market growth.
  
•   Presence of strong pipeline of drugs under trial is expected to spur market growth during the forecast period.
  

Restraints:

•   Whereas, high cost of treatment for SBS is expected to restrain market growth during the forecast period.
  

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The short bowel syndrome market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the short bowel syndrome market in these regions.

IMPACT OF COVID-19 ON SHORT BOWEL SYNDROME MARKET

COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.

Short Bowel Syndrome Market Report Analysis

Short Bowel Syndrome Market

• 
  CAGR (2023 - 2031)

  XX%
• Market Size 2023
  US$ XX Million
• Market Size 2031
  US$ XX Million

Report Coverage

• Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope

• Key future trends
• Detailed PEST/Porter’s Five Forces and SWOT analysis

• Industry landscape and competition analysis & recent developments
• Detailed company profiles

• Global and regional market analysis covering key market trends, major players, regulations, and recent market developments

Key Players

• Takeda Pharmaceutical Company Limited
• Zealand Pharma A/S
• VectivBio AG
• 9 Meters Biopharma, Inc
• Hanmi Pharm.Co.,Ltd
• GlaxoSmithKline, Plc
• Cadila Pharmaceuticals
• Sun Pharmaceutical Industries Ltd
• Troikaa

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

By Drug class

• Glucagon-like Peptide
• H2 Blockers
• Proton Pump Inhibitors

By Distribution channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Sales

MARKET PLAYERS

The report covers key developments in the short bowel syndrome market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from short bowel syndrome market are anticipated to lucrative growth opportunities in the future with the rising demand for short bowel syndrome in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the short bowel syndrome market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

•   Takeda Pharmaceutical Company Limited
  
•   Zealand Pharma A/S
  
•   VectivBio AG
  
•   9 Meters Biopharma, Inc
  
•   Hanmi Pharm.Co.,Ltd
  
•   GlaxoSmithKline, Plc
  
•   Cadila Pharmaceuticals
  
•   Sun Pharmaceutical Industries Ltd
  
•   Troikaa
  
•   AJANTA PHARMA
  

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Short Bowel Syndrome Report Scope